JUL 09, 2019 8:06 AM PDT

Self-Destructing Cancer: Study Stops Chain Reaction of Tumor Growth

WRITTEN BY: Julia Travers

Scientists are constantly exploring new ways to halt cancer in its tracks and make it harder for it to grow, adapt and spread. A new study out of the Perelman School of Medicine at the University of Pennsylvania reveals that stopping one protein from functioning can cause some cancer cells to die from stress.

During this study, published in July in the journal Nature Cell Biology, researchers concentrated on cancers driven by a gene called MYC. MYC contributes to the growth of at least 40 percent of tumors in people. When MYC functions normally, it controls cell growth. When it is mutated in cancer, it cues a process that causes unmitigated tumor growth. Targeting MYC specifically has not yet been mastered, so scientists are focusing on other key players in the related tumor growth process.

The team, headed up by Dr. Constantinos Koumenis, Richard Chamberlain professor of Radiation Oncology and vice-chair and research division director of Radiation Oncology, is exploring the series of events that occur when MYC triggers tumor growth. In the past, they targeted an enzyme called PERK, which plays a role in the chain reaction. However, it was discovered that controlling PERK does not always slow cancer growth, because the MYC gene has another redundant path that moves the growth process forward. At a further step along the chain reaction, where these two signal pathways converge, is a protein called ATF4, which ends up being central to this exploration. The researchers found that instead of working upstream with PERK, looking downstream at stopping ATF4 was more effective.

Research image, public domain

"What we've learned is that we need to go further downstream to block tumor growth in a way that cancer cells can't easily escape, and our study identifies the target to do just that," Koumenis said. Koumenis is the study’s co-senior author with Dr. Davide Ruggero, a professor of Urology in the Helen Diller Family Comprehensive Cancer Center at the University of California.

ATF4 turns on the genes MYC needs to grow and controls the rate of some of the protein production in cells. When researchers blocked ATF4 in cell lines and mice, tumors built up too many proteins and died of stress. This process stopped the growth of tumors in mice with both colorectal cancer and lymphomas. The researchers also found tumors in humans driven by MYC display over-expression of ATF4 and its protein partners, “which is further evidence that these findings may point to an approach that could work for humans,” Penn Medicine News explains. It states the researchers may have effectively found MYC's "Achilles’ Heel" and a way to make cancer self-destruct.

Cell growth image, public domain

"This shows us the potential impacts of targeting ATF4 in MYC-dependent tumors, something we're already studying. We're also working to confirm this approach will not cause any serious off-target effects," lead author Dr Feven Tameire, said. Ongoing research will also look into how ATF4 works and other potential targets in the cancer’s chain reaction.

Sources:

Science Focus

University of Pennsylvania

Nature Cell Biology

 
About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech, conservation and the arts. She enjoys solutions journalism. Find more of her work at jtravers.journoportfolio.com.
You May Also Like
JUL 27, 2020
Cancer
Identifying Tumor Cells in the Blood with Artificial Intelligence
JUL 27, 2020
Identifying Tumor Cells in the Blood with Artificial Intelligence
Cancer diagnostics is an area of keen interest in the fight against cancer. Cancer often slips by routine checkups and v ...
AUG 07, 2020
Cancer
Immune-Related Genes as Prognostic Biomarkers
AUG 07, 2020
Immune-Related Genes as Prognostic Biomarkers
Cancer is one of the most persistent and hardy diseases. Cancers often develop the ability to suppress the immune system ...
AUG 13, 2020
Clinical & Molecular DX
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
AUG 13, 2020
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
A staggering 1 in 8 women in the U.S. will develop an aggressive form of breast cancer in their lifetime, making it the ...
SEP 16, 2020
Cancer
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
SEP 16, 2020
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
The last decade has seen the emergence of several new therapies against cancer. For melanoma, checkpoint inhibitors have ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
SEP 21, 2020
Cancer
Black women have delayed and longer breast cancer treatment
SEP 21, 2020
Black women have delayed and longer breast cancer treatment
A study led by UNC Lineberger Comprehensive Cancer Center researchers has quantified the healthcare inequities in cancer ...
Loading Comments...